Sarah Louise Nickels

Sarah Louise Nickels

Auto-generated profile, based on publicly available information

Sarah Louise Nickels

Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 6, Avenue du Swing, L-4367 Belvaux, Luxembourg

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in Glia
Verified
Journal Article
Open access
SSSonia Sabate‐Soler
Sonia Sabate‐Soler
SNSarah Louise Nickels
Sarah Louise Nickels
CSClaudia Saraiva
Claudia Saraiva
EBEmanuel Berger
Emanuel Berger
UDUgne Dubonyte
Ugne Dubonyte
JSJens Schwamborn
Jens Schwamborn
The human brain is a complex, three‐dimensional structure. To better recapitulate brain complexity, recent efforts have focused on the development of human‐specific midbrain organoids. Human iPSC‐derived midbrain organoids consist of differentiated and functional neurons, which contain active synapses, as well as astrocytes and oligodendrocytes. However, the absence of microglia, with their ability to remodel neuronal networks and phagocytose apoptotic cells and debris, represents a major disadvantage for the current midbrain organoid systems. Additionally, neuroinflammation‐related disease modeling is not possible in the absence of microglia. So far, no studies about the effects of human iPSC‐derived microglia on midbrain organoid neural cells have been published. Here we describe an approach to derive microglia from human iPSCs and integrate them into iPSC‐derived midbrain organoids. Using single nuclear RNA Sequencing, we provide a detailed characterization of microglia in midbrain organoids as well as the influence of their presence on the other cells of the organoids. Furthermore, we describe the effects that microglia have on cell death and oxidative stress‐related gene expression. Finally, we show that microglia in midbrain organoids affect synaptic remodeling and increase neuronal excitability. Altogether, we show a more suitable system to further investigate brain development, as well as neurodegenerative diseases and neuroinflammation.

21 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EZElisa Zuccoli
Elisa Zuccoli
HSHaya Al Sawaf
Haya Al Sawaf
MTMona Tuzza
Mona Tuzza
SNSarah Nickels
Sarah Nickels
AZAlise Zagare
Alise Zagare
JSJens Schwamborn
Jens Schwamborn
Midbrain organoids are advanced in vitro cellular models for disease modelling. They have been used successfully over the past decade for Parkinson’s disease (PD) research and drug development. The three-dimensional structure and multicellular composition allow disease research under more physiological conditions than is possible with conventional 2D cellular models. However, there are concerns in the field regarding the organoid batch-to-batch variability and thus the reproducibility of the results. In this manuscript, we generate multiple independent midbrain organoid batches derived from healthy individuals or GBA-N370S mutation-carrying PD patients to evaluate the reproducibility of the GBA-N370S mutation-associated PD transcriptomic and metabolic signature as well as selected protein abundance. Our analysis shows that GBA-PD-associated phenotypes are reproducible across organoid generation batches and time points. This proves that midbrain organoids are not only suitable for PD in vitro modelling, but also represent robust and highly reproducible cellular models.

24 January 2025 in Parkinson's Disease
Verified
Journal Article
Open access
KMKathleen Michèle Ghislaine Marie Mommaerts
Kathleen Michèle Ghislaine Marie Mommaerts
AMAnna S. Monzel
Anna S. Monzel
AZAlise Zagare
Alise Zagare
SNSarah L. Nickels
Sarah L. Nickels
NDNico J. Diederich
Nico J. Diederich
JSJens Schwamborn
Jens Schwamborn
Parkinson’s disease is an age‐related progressive neurodegenerative disorder. A large majority of Parkinson’s disease patients have an unknown etiology, which is classified as idiopathic Parkinson’s disease. Generating disease models directly from idiopathic Parkinson’s disease patients may improve the understanding of the disease pathology. Both neuroprotective and neurodegenerative roles have been suggested for cystatin C in neurodegenerative disease. In Parkinson’s disease, investigations assessing cystatin C levels in different types of biospecimens such as blood, cerebrospinal fluid, and in vitro models have had conflicting results. We present a study assessing cystatin C levels in different biospecimen types originating from the same subjects. Using a sandwich ELISA, we compared cystatin C concentration in blood derivatives (plasma and serum) and culture media of derived models (stem cells, neuroepithelial stem cells, and midbrain organoids) of three idiopathic Parkinson’s disease and three age‐matched healthy control subjects with the same CST3 genotype. Genotyping analyses confirmed that all subjects were homozygous AA. The identity of the derived models was confirmed using immunohistochemical staining. Secreted cystatin C concentration was measured in each biospecimen tested. No statistically significant differences in cystatin C concentrations were found between the subjects in any of the biospecimen types. As a personalized marker, a higher cystatin C concentration was shown for some individual patients in the culture medium of midbrain organoids, suggesting a potential involvement in Parkinson’s disease physiopathology. This proof of concept demonstrates that cystatin C is secreted by various idiopathic Parkinson’s disease cell models, including midbrain organoids, which in turn suggests that cystatin C secretion by midbrain organoids might be pertinent in neurodegenerative disease research.